For NSCLCs harboring KRASG12C mutations (representing more than 40% of the most frequent KRAS mutation in lung cancer), sotorasib, an allele-specific covalent inhibitor, received accelerated approval by the FDA in May 2021 and showed efficacy in certain subgroups during clinical trials [7,8]. Here, KRAS is linked to lung carcinoma.